Clinical importance of PCA3 lncRNA aberrant expression in chronic myeloid leukemia patients: a comparative method

Abstract

Abstract Objectives Long noncoding RNAs (lncRNAs) plays important role in disease spread and its invasion. Overexpression of prostate cancer antigen 3 gene (PCA3gene) is reported in prostate cancer. To analyze the PCA3 lncRNA expression in chronic myeloid leukemia (CML) patients. Methods The study included clinically confirmed 100 CML patients and 100 healthy subjects. Relative quantification using Sybr Green dye was used to calculate the PCA3 lncRNAs expression. Total RNA was extracted by TRIzol method and quantitative real-time polymerase chain reaction. Results In CML patients, 9.96 ± 4.77-folds increased noncoding PCA3 lncRNA expression was observed compared to healthy subjects. Patients of chronic phase, accelerated phase, and blast crisis phase had 4.46 ± 1.36, 7.31 ± 3.10, and 12.91 ± 4.85-fold PCA3 lncRNA expression compared to healthy subjects (p<0.0001), respectively. CML patients who have a complaint of splenomegaly had higher PCA3 lncRNA expression than those who did not complain splenomegaly compared to healthy subjects (12.04 ± 5.02-fold vs. 6.09 ± 3.39-fold, p<0.0001). Patients who had ≤20,000 TLC showed fewer PCA3 lncRNA expression than those who had >20 thousand of TLC (4.45 ± 1.84 vs. 11.25 ± 5.05, p<0.0001). Receiver operating characteristic showed correlation of PCA3 lncRNA expression with severity of cancer. Conclusions lncRNA PCA3 expression to be linked with different stages of the disease and a prognostic indicator for disease in CML patients.